MedTrace Logo

Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines

NCT02563678 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-08-04

No results posted yet for this study

Summary

In this small pilot study, participants (patients and healthy volunteers) will have blood drawn before and after the study intervention (hyperbaric chamber session or normal pressure oxygen breathing. This blood will be analyzed for neutrophil oxidative burst and cytokine analysis.

Conditions

Interventions

DRUG

Hyperbaric Oxygen

Hyperbaric oxygen therapy

OTHER

Hyperbaric Air/Oxygen

Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber

OTHER

Normobaric oxygen

Breathing 100% oxygen at normal, atmospheric pressure

Sponsors & Collaborators

  • Intermountain Health Care, Inc.

    lead OTHER

Principal Investigators

  • Lindell K Weaver, MD · Intermountain Health Care, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02563678 on ClinicalTrials.gov